We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

WONDFO

Wondfo is a high-tech biological company focusing providing professional products and services for rapid diagnosis an... read more Featured Products: More products

Download Mobile App





Wondfo Exhibits Automatic Bench-Top CLIA Analyzers for POC Testing at AACC 2022

By LabMedica International staff writers
Posted on 26 Jul 2022

Wondfo (Guangzhou, China) will be exhibiting its automatic bench-top chemiluminescence immunoassay (CLIA) analyzers with advanced features for point of care (POC) testing at the 2022 AACC Clinical Lab Expo. More...



At AAC 2022, Wondfo is presenting its compact and automatic Accre 8 and Accre 90 CLIA bench-top analyzers which are 70% smaller than ordinary CLIA analyzers. With a single-dose reagent cartridge, the analyzers allow 600 days MTBF, requiring no extra consumables. The Accre 8 and Accre 90 enjoy both simple operation requiring only 30-minute training and reliable calibration & quality control system. Both the analyzers have a TAT time of 12-40 minutes and offer high sensitivity.

The Accre 8 has a throughput of up to 36 tests/hour and offers carry-over prevention. The Accre 90 has a throughput of up to 96 tests/hour and enables simultaneous processing of difference parameters with carry-over prevention. The Accre 8 and Accre 90 are designed for multiple application scenarios in emergency care, primary care and laboratories. Both the analyzers offer a broad menu of tests in the areas of thyroid, fertility, tumors, infectious diseases, cardiac, anemia, inflammation, bone metabolism and glycol metabolism.
 

Related Links:
Wondfo 


New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
New
HPV Test
Allplex HPV28 Detection
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.